Menu
Search
|

Menu

Close
X

NuCana PLC NCNA.OQ (NASDAQ Stock Exchange Global Select Market)

23.96 USD
-0.79 (-3.19%)
As of 8:05 PM BST
chart
Previous Close 24.75
Open 24.08
Volume 1,358
3m Avg Volume 14,755
Today’s High 24.15
Today’s Low 23.96
52 Week High 30.80
52 Week Low 9.48
Shares Outstanding (mil) 30.88
Market Capitalization (mil) 522.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, GBP)
FY18
0
FY17
0
EPS (GBP)
FY18
-0.200
FY17
-0.070
*Note: Units in Millions of British Pounds
**Note: Units in British Pounds

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
18.71
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Christopher Wood
Chairman of the Board, Co-Founder & Chief Medical Officer, Since
Salary: --
Bonus: --
Hugh Griffith
Chief Executive Officer, Founder, Director, Since
Salary: --
Bonus: --
Donald Munoz
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Martin Mellish
Non-Executive Director, Since
Salary: --
Bonus: --
Rafaele Tordjman
Non-Executive Director, Since 2011
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3 Lochside Way
EDINBURGH     EH12 9DT

Phone: +44131.2483660

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

SPONSORED STORIES